RT Journal Article
SR Electronic
T1 Deep Learning and Single Cell Phenotyping for Rapid Antimicrobial Susceptibility Testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.08.22283219
DO 10.1101/2022.12.08.22283219
A1 Zagajewski, Aleksander
A1 Turner, Piers
A1 Feehily, Conor
A1 El Sayyed, Hafez
A1 Andersson, Monique
A1 Barrett, Lucinda
A1 Oakley, Sarah
A1 Stracy, Mathew
A1 Crook, Derrick
A1 Nellåker, Christoffer
A1 Stoesser, Nicole
A1 Kapanidis, Achillefs N.
YR 2022
UL http://medrxiv.org/content/early/2022/12/09/2022.12.08.22283219.abstract
AB The rise of antimicrobial resistance (AMR) is one of the greatest public health challenges, already causing up to 1.2 million deaths annually and rising. Current gold-standard antimicrobial susceptibility tests (ASTs) are low-throughput and can take up to 48 hours, with implications for patient care. We present advances towards a novel, rapid AST, based on the deep-learning of single-cell specific phenotypes directly associated with antimicrobial susceptibility in Escherichia coli. Our models can reliably (80% single-cell accuracy) classify untreated and treated susceptible cells, across a range of antibiotics and phenotypes - including phenotypes not visually distinct to a trained, human observer. Applying models trained on lab-reference susceptible strains to clinical isolates of E. coli treated with ciprofloxacin, we demonstrate our models reveal significant (p<0.001) differences between resistant and susceptible populations, around a fixed treatment level. Conversely, deploying on cells treated with a range of ciprofloxacin concentrations, we show single-cell phenotyping has the potential to provide equivalent information to a 24-hour growth AST assay, but in as little as 30 minutes.Competing Interest StatementThe work was carried out using a wide-field microscope from Oxford Nanoimaging, a company in which ANK is a co-founder and shareholder. ANK received no payment for this work from Oxford Nanoimaging, and Oxford Nanoimaging was not involved in any aspect of this work.Funding StatementThis work was supported by an Oxford Martin School (by the establishment of the Oxford Martin School Programme on Antimicrobial Resistance Testing; to ANK, NS, CN, DC, and MA), by Wellcome Trust grant 110164/Z/15/Z (to ANK) and by UK Biotechnology and Biological Sciences Research Council grants BB/N018656/1 and BB/S008896/1 (to ANK). The work was also supported by an UK Engineering and Physical Sciences Research Council funded scholarship (to AZ), part of the Oxford-Nottingham Biomedical Imaging Centre for Doctoral Training grant EP/L016052/1. The research was additionally supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (NIHR200915) at the University of Oxford in partnership with United Kingdom Health Security Agency (UKHSA) and by the NIHR Oxford Biomedical Research Centre. NS is an NIHR Oxford BRC Senior Research Fellow.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London - Queen Square Research Ethics Committee of the UK Health Research Authority gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study, including micrographs of treated and untreated cells, ground-truth annotations and trained models used to evaluate results are available from the corresponding author upon reasonable request.